- China
- /
- Medical Equipment
- /
- SZSE:300888
Estimating The Fair Value Of Winner Medical Co., Ltd. (SZSE:300888)
Key Insights
- The projected fair value for Winner Medical is CN¥28.81 based on 2 Stage Free Cash Flow to Equity
- With CN¥25.22 share price, Winner Medical appears to be trading close to its estimated fair value
- Our fair value estimate is 24% lower than Winner Medical's analyst price target of CN¥37.77
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Winner Medical Co., Ltd. (SZSE:300888) as an investment opportunity by taking the expected future cash flows and discounting them to today's value. This will be done using the Discounted Cash Flow (DCF) model. Models like these may appear beyond the comprehension of a lay person, but they're fairly easy to follow.
Remember though, that there are many ways to estimate a company's value, and a DCF is just one method. For those who are keen learners of equity analysis, the Simply Wall St analysis model here may be something of interest to you.
View our latest analysis for Winner Medical
Is Winner Medical Fairly Valued?
We use what is known as a 2-stage model, which simply means we have two different periods of growth rates for the company's cash flows. Generally the first stage is higher growth, and the second stage is a lower growth phase. To start off with, we need to estimate the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, and so the sum of these future cash flows is then discounted to today's value:
10-year free cash flow (FCF) estimate
2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | |
Levered FCF (CN¥, Millions) | CN¥805.0m | CN¥923.0m | CN¥918.2m | CN¥922.6m | CN¥933.7m | CN¥949.5m | CN¥968.8m | CN¥991.0m | CN¥1.02b | CN¥1.04b |
Growth Rate Estimate Source | Analyst x1 | Analyst x1 | Est @ -0.52% | Est @ 0.49% | Est @ 1.20% | Est @ 1.69% | Est @ 2.04% | Est @ 2.28% | Est @ 2.45% | Est @ 2.57% |
Present Value (CN¥, Millions) Discounted @ 7.7% | CN¥747 | CN¥796 | CN¥735 | CN¥685 | CN¥644 | CN¥608 | CN¥576 | CN¥547 | CN¥520 | CN¥495 |
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = CN¥6.4b
We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 2.9%. We discount the terminal cash flows to today's value at a cost of equity of 7.7%.
Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = CN¥1.0b× (1 + 2.9%) ÷ (7.7%– 2.9%) = CN¥22b
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= CN¥22b÷ ( 1 + 7.7%)10= CN¥10b
The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is CN¥17b. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Compared to the current share price of CN¥25.2, the company appears about fair value at a 12% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind.
Important Assumptions
Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Winner Medical as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 7.7%, which is based on a levered beta of 0.977. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for Winner Medical
- Debt is not viewed as a risk.
- Dividends are covered by earnings and cash flows.
- Earnings declined over the past year.
- Dividend is low compared to the top 25% of dividend payers in the Medical Equipment market.
- Annual earnings are forecast to grow faster than the Chinese market.
- Current share price is below our estimate of fair value.
- Annual revenue is forecast to grow slower than the Chinese market.
Next Steps:
Whilst important, the DCF calculation shouldn't be the only metric you look at when researching a company. DCF models are not the be-all and end-all of investment valuation. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. For Winner Medical, there are three fundamental factors you should assess:
- Risks: As an example, we've found 2 warning signs for Winner Medical that you need to consider before investing here.
- Future Earnings: How does 300888's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!
PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the SZSE every day. If you want to find the calculation for other stocks just search here.
Valuation is complex, but we're here to simplify it.
Discover if Winner Medical might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SZSE:300888
Winner Medical
Engages in the research and development, manufacture, and marketing of cotton-based medical dressings and medical disposables, and consumer products in China.
Excellent balance sheet with moderate growth potential.